Next 10 |
2024-05-15 20:28:09 ET Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript May 15, 2024 04:30 PM ET Company Participants Roger Weiss - Investor Relations Joshua Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Pa...
2024-05-15 17:18:00 ET More on Aytu BioScience Seeking Alpha’s Quant Rating on Aytu BioScience Historical earnings data for Aytu BioScience Financial information for Aytu BioScience Read the full article on Seeking Alpha For further details see...
2024-05-15 16:21:05 ET More on Aytu BioScience Seeking Alpha’s Quant Rating on Aytu BioScience Historical earnings data for Aytu BioScience Financial information for Aytu BioScience Read the full article on Seeking Alpha For further details see...
2024-05-14 15:26:47 ET More on Aytu BioScience Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Aytu BioScience Historical earnings data for Aytu BioScience Financial information for Aytu BioScience ...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024...
2024-02-14 22:52:09 ET Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Conference Call February 14, 2024 16:30 ET Company Participants Roger Weiss - Investor Relations Joshua Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call ...
2024-02-14 16:20:46 ET More on Aytu BioScience Seeking Alpha’s Quant Rating on Aytu BioScience Historical earnings data for Aytu BioScience Financial information for Aytu BioScience Read the full article on Seeking Alpha For further details see...
Q2 2024 operating income of $2.4 million Q2 2024 net loss of $0.2 million and adjusted EBITDA 1 of $5.1 million Q2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 million Q2 2024 ADHD Portfolio net revenue up 49% compared to Q2...
Owens Corning Inc New (OC) is expected to report $2.82 for Q4 2023 Getty Realty Corporation (GTY) is expected to report $0.56 for Q4 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q2 2024 Nexien BioPharma Inc (NXEN) is expected to report for Q2 2024 Ayt...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024...
Q2 2024 operating income of $2.4 million Q2 2024 net loss of $0.2 million and adjusted EBITDA 1 of $5.1 million Q2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 million Q2 2024 ADHD Portfolio net revenue up 49% compared to Q2...